OTCMKTS:BIOAF - biOasis Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.3570 +0.06 (+20.20 %)
(As of 12/14/2018 09:46 AM ET)
Previous Close$0.3009
Today's Range$0.33 - $0.3570
52-Week Range$0.2096 - $0.7435
Volume4,000 shs
Average Volume15,193 shs
Market Capitalization$17.63 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the blood-brain barrier; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program. It also has a strategic collaboration with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.

Receive BIOAF News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOAF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BIOAF
Previous Symbol
CUSIPN/A
Phone203-390-7395

Debt

Debt-to-Equity RatioN/A
Current Ratio2.16
Quick Ratio2.16

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$460,000.00
Price / Sales45.47
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.01 per share
Price / Book35.70

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-4,120,000.00
Net Margins-1,517.77%
Return on Equity-407.59%
Return on Assets-264.48%

Miscellaneous

EmployeesN/A
Outstanding Shares58,590,000
Market Cap$17.63 million
OptionableNot Optionable

biOasis Technologies (OTCMKTS:BIOAF) Frequently Asked Questions

What is biOasis Technologies' stock symbol?

biOasis Technologies trades on the OTCMKTS under the ticker symbol "BIOAF."

How were biOasis Technologies' earnings last quarter?

biOasis Technologies Inc (OTCMKTS:BIOAF) released its quarterly earnings results on Tuesday, October, 30th. The company reported ($0.01) earnings per share (EPS) for the quarter. biOasis Technologies had a negative net margin of 1,517.77% and a negative return on equity of 407.59%. View biOasis Technologies' Earnings History.

When is biOasis Technologies' next earnings date?

biOasis Technologies is scheduled to release their next quarterly earnings announcement on Monday, February 4th 2019. View Earnings Estimates for biOasis Technologies.

Has biOasis Technologies been receiving favorable news coverage?

Headlines about BIOAF stock have been trending somewhat positive on Friday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. biOasis Technologies earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Who are some of biOasis Technologies' key competitors?

Who are biOasis Technologies' key executives?

biOasis Technologies' management team includes the folowing people:
  • Dr. Mark Day, Interim CFO, CEO, Pres, Chief Scientist & Director
  • Ms. Catherine London, Exec. VP and Head of Corp. Communications & Investor Relations
  • Mr. Kim Elton, Director of Marketing
  • Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer
  • Dr. Caroline Hill, Sr. VP & Head of R&D Operations

How do I buy shares of biOasis Technologies?

Shares of BIOAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is biOasis Technologies' stock price today?

One share of BIOAF stock can currently be purchased for approximately $0.3570.

How big of a company is biOasis Technologies?

biOasis Technologies has a market capitalization of $17.63 million and generates $460,000.00 in revenue each year.

What is biOasis Technologies' official website?

The official website for biOasis Technologies is http://www.bioasis.us.

How can I contact biOasis Technologies?

biOasis Technologies' mailing address is 14 Water Street, Guilford CT, 06437. The company can be reached via phone at 203-390-7395 or via email at [email protected]


MarketBeat Community Rating for biOasis Technologies (OTCMKTS BIOAF)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  74
MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote "Outperform" if you believe BIOAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Featured Article: Cost of Debt

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel